[Evaluation of the use of rifampin combinations in severe staphylococcal infections. Apropos of the selection of 7 resistant mutants].
Selection of rifampicin-resistant Staphylococcus aureus has been described in vitro and in vivo when this compound is given as monotherapy or orally. That this occurrence may be prevented by combination antibiotic therapy is generally accepted. We report 25 cases of severe staphylococcal infection treated by a synergistic association of rifampicin with an aminoglycoside, vancomycin, or a macrolide. Therapy failed as a result of selection of the same rifampicin-resistant Staphylococcus aureus (serotype and lysotype) in seven cases. This finding may be explained by insufficient diffusion or inactivation of the other antibiotic in the infection site.
D000293:Adolescent; D000328:Adult; D000368:Aged; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D012293:Rifampin / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects / Q000235:genetics
D012293:Rifampin
Evaluation de l'utilisation de la rifampicine en association dans les staphylococcies graves. A propos de la sélection de sept mutants résistants.